Relmada's rapid-acting NMDA depression drug expected to fail second Phase 3

Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. The study’s data monitoring committee said the ...